CANC
Tema Oncology ETF
$44.05
$-0.31 (-0.70%)
Delayed ≥20 min · Sep 3, 2026
Key Statistics
Net Assets (AUM)
$213.20M
Expense Ratio
See prospectus
Previous Close
$44.36
Day Range
$43.92 – $44.36
52-Week Range
$26.62 – $47.00
Volume
29.16K
Avg Vol (50D)
-
Beta
0.69
Historical Performance
1M
+5.65%
3M
+20.92%
6M
+19.58%
YTD
+26.87%
1Y
+62.75%
3Y
+83.19%
5Y
—
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
RVMD Revolution Medicines Inc
6.29%
NOVN Novartis AG
4.96%
BBIO Bridgebio Pharma Inc
4.75%
AZN AstraZeneca PLC
4.63%
LLY Eli Lilly & Co
4.32%
BMY Bristol-Myers Squibb Co
4.22%
RHHBY Roche Holding AG
4.06%
MRK Merck & Co Inc
3.84%
ACLX Arcellx Inc
3.44%
COGT Cogent Biosciences Inc
3.29%
NUVL Nuvalent Inc
3.14%
GMAB Genmab A/S
3.13%
IMNM Immunome Inc
2.67%
JNJ Johnson & Johnson
2.53%
CELC Celcuity Inc
2.47%
AMGN Amgen Inc
2.46%
ABBV AbbVie Inc
2.43%
EXEL Exelixis Inc
2.19%
IDYA Ideaya Biosciences Inc
1.80%
ONC BeOne Medicines Ltd
1.78%
SNDX Syndax Pharmaceuticals Inc
1.73%
CGON CG oncology Inc
1.69%
ZLAB Zai Lab Ltd
1.46%
ERAS Erasca Inc
1.45%
ZYME Zymeworks Inc
1.41%
Top 25 holdings as of Feb 28, 2026 · source: SEC N-PORT. Full holdings & prospectus →
CANC News
- Discipline and Rules-Based Execution in CANC Response
- Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
- Short Interest in Tema Oncology ETF (NASDAQ:CANC) Declines By 47.3%
- Biotech ETF (CANC) Hits New 52-Week High
- (CANC) Volatility Zones as Tactical Triggers
- Price-Driven Insight from (CANC) for Rule-Based Strategy
- (CANC) Price Dynamics and Execution-Aware Positioning
- (CANC) Price Dynamics and Execution-Aware Positioning
- (CANC) as a Liquidity Pulse for Institutional Tactics
- (CANC) Risk Channels and Responsive Allocation
Data for CANC is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.